MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that three abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in Orlando, Florida from December 5-8, 2015. The abstracts were published today on the ASH website at www.hematology.org.
Oral Presentations
Two abstracts containing clinical data on imetelstat were selected for oral presentation. One abstract contains an analysis of preliminary safety and efficacy data from a pilot study of patients with a subtype of myelodysplastic syndromes known as refractory anemia with ring sideroblasts. The second abstract contains an analysis of mutations detected in essential thrombocythemia patients treated with imetelstat. The abstract supplements a prior analysis of JAK2V617F and CALR mutations presented at the ASH Annual Meeting in December 2014.
Title: Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis (Abstract #55)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Early and Late Stage Trials in MPN
Session Date: Saturday, December 5, 2015
Session Time: 9:30 a.m. ET - 11:00 a.m. ET
Presentation Time: 9:30 a.m. ET
Title: Dynamics of Mutations in Patients with ET Treated with Imetelstat (Abstract #57)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Early and Late Stage Trials in MPN
Session Date: Saturday, December 5, 2015
Session Time: 9:30 a.m. ET - 11:00 a.m. ET
Presentation Time: 10:00 a.m. ET
Poster Presentation
One abstract containing non-clinical data on imetelstat was selected for presentation as a poster. In this study, the investigators evaluated the activity of imetelstat in a non-clinical model of acute myeloid leukemia, to potentially support broader clinical development of the drug.
Title: Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced by DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status (Abstract #1267)
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
Session Date: Saturday, December 5, 2015
Session Time: 5:30 p.m. - 7:30 p.m. ET
In accordance with ASH policies, abstracts submitted to the ASH Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the ASH Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the ASH Annual Meeting.
Webcast Investor Event
Management will be hosting a live webcast of an analyst and investor meeting at 12:15 p.m. ET on December 5, 2015 to discuss the imetelstat data presented at the ASH Annual Meeting. The audio and slide presentation will be accessible at www.geron.com on the Investor Relations pages, under Events. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.